Zydus launches India’s first trivalent influenza vaccine, VaxiFlu

Zydus Lifesciences Ltd. announced the launch of VaxiFlu™, India's first trivalent influenza vaccine, on September 2, 2025. This new vaccine aligns with the World Health Organisation (WHO)'s 2025-26 recommendations for Northern Hemisphere strains, which include A/Victoria/4897/2022 (H1N1)pdm09-like, A/Croatia/10136RV/2023 (H3N2)-like, and B/Austria/1359417/2021 (B/Victoria lineage)-like viruses. The Centre for Disease Control (NCDC), Government of India, has also recommended the use of trivalent influenza vaccines for the 2025-26 season.

The introduction of VaxiFlu™ comes as seasonal influenza continues to be a significant global health concern, causing 3–5 million severe illnesses and 290,000 to 650,000 respiratory deaths annually worldwide. Experts emphasize that the persistent absence of the B/Yamagata lineage virus since March 2020 means its inclusion in vaccine formulations is no longer necessary. VaxiFlu™ is recommended for individuals aged six months and above.

Zydus Lifesciences, a global innovation-led healthcare company, employs over 28,000 people and has 1,500 scientists engaged in R&D. The company aims to provide quality healthcare solutions, transforming lives through path-breaking discoveries.